Beloc
In brief
- In our pharmacy, you can buy Beloc without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
- Beloc (metoprolol) treats hypertension, angina and arrhythmias, and prevents migraines. It works by blocking beta-1 receptors, reducing heart rate and blood pressure.
- The usual dose is 50-100 mg daily for immediate-release tablets, or 100 mg daily for modified-release formulations.
- Administered orally as tablets (immediate-release or modified-release) or intravenously in hospital settings.
- Onset occurs within 15–60 minutes for immediate-release tablets and 1–4 hours for modified-release formulations.
- Duration of action is 6–12 hours for immediate-release and 24 hours for modified-release tablets.
- Avoid alcohol consumption, as it may intensify dizziness and blood pressure-lowering effects.
- The most common side effects include fatigue, dizziness, and cold extremities.
- Would you like to try Beloc without a prescription?
Basic Beloc information
| Characteristic | Details |
| INN (International Nonproprietary Name) | Metoprolol |
| Brand names in UK | Betaloc, Lopresor, generic metoprolol tartrate |
| ATC Code | C07AB02 (cardiovascular system; selective beta-blockers) |
| Forms & dosages | Immediate-release tablets (25mg, 50mg, 100mg), modified-release tablets, intravenous ampoules (1mg/ml – clinical settings) |
| Manufacturers | AstraZeneca (original), generics by Sandoz and Teva |
| Registration status in UK | Licensed by the MHRA |
| Prescription classification | Prescription-only medicine (POM) |
Beloc contains the active substance metoprolol, classified pharmacologically as a beta-1-selective adrenergic blocker. In the UK, metoprolol is available as Betaloc, Lopresor and generic tablets. Metoprolol preparations fall into two principal categories: immediate-release and modified-release formulations. These differences significantly impact dosing frequency and clinical applications.
The medication holds current licensing from the Medicines and Healthcare products Regulatory Agency (MHRA). All metoprolol preparations require a valid prescription in the United Kingdom, with dispensing on NHS or private prescription. Packaging varies by manufacturer but generally consists of foil-sealed blister packs containing 28-56 tablets, designed to maintain stability in typical UK household storage conditions.
Pharmacology & mechanism of action
Beloc (metoprolol) functions by selectively blocking beta-1 adrenergic receptors primarily located in cardiac tissue. This targeted action reduces the heart's response to adrenaline and noradrenaline, resulting in three key physiological effects: decreased heart rate, lowered blood pressure, and reduced myocardial oxygen consumption. Such mechanisms underlie its clinical benefits for cardiac conditions like hypertension and angina pectoris.
The pharmacokinetic profile of metoprolol varies significantly between formulations. Immediate-release tablets exhibit rapid absorption through the gastrointestinal tract, reaching peak concentration within 1-2 hours, while modified-release formulations demonstrate prolonged absorption characteristics. Metoprolol undergoes extensive hepatic metabolism primarily via the CYP2D6 enzyme pathway, creating important considerations for patients with liver impairment or those taking interacting medications. Elimination occurs predominantly through renal excretion of metabolites, with an elimination half-life of about 3-7 hours; modified-release preparations prolong absorption rather than elimination.
Clinically significant interactions exist with several medication classes. Concomitant use with verapamil or related calcium channel blockers potentiates cardiac depression, while NSAIDs like ibuprofen may reduce antihypertensive efficacy. Alcohol consumption exacerbates hypotension, demanding avoidance. Patients should always inform healthcare providers of all current medications before initiating metoprolol therapy.
Approved and off-label indications
Metoprolol holds licensed approval in the United Kingdom for multiple cardiovascular and neurological conditions:
- Chronic hypertension management through sustained blood pressure reduction
- Angina pectoris treatment to prevent cardiac chest pain episodes
- Post-myocardial infarction care to reduce mortality risk
- Prophylactic migraine management to reduce attack frequency
Certain off-label applications exist within UK clinical practice despite lacking formal licensing. These include management of essential tremor affecting hands and head, performance anxiety ("stage fright") mitigation, and specific arrhythmias like inappropriate sinus tachycardia. Such applications remain based on clinical experience rather than formal regulatory approval.
Special population considerations:
- Pregnancy/lactation: Use only if clearly needed, under medical supervision, due to risks including fetal bradycardia
- Elderly: Typically start therapy at lower doses
- Hepatic impairment: Significant dose reductions needed due to metabolism pathway
- Paediatrics: Not routinely used in children
Standard dosages & administration protocols
| Clinical indication | Standard UK regimen |
| Essential hypertension | Initial: 100mg daily. Maintenance: up to 400mg daily based on response. |
| Migraine prophylaxis | 100-200mg daily, typically in divided doses of immediate-release tablets. |
| Angina: 50-100mg immediate-release 2-3x daily Post-MI: IV formulation (hospital) followed by oral regimen |
|
Proper administration significantly impacts medication effectiveness and tolerability:
Administration guidance: Consume tablets with food to minimise gastrointestinal discomfort. Extended-release preparations must be swallowed whole with fluids. Never crush, split, or chew these formulations, as this disrupts the controlled-release mechanism and alters plasma concentrations. Storage requires protection from moisture and high temperatures, ideally below 25°C in original packaging.
Missed doses require cautious management. If a dose is missed, take it as soon as possible unless it is within 6 hours of the next scheduled dose for immediate-release formulations, or 12 hours for extended-release preparations. Never administer double doses to compensate. On discontinuation, gradually taper under medical supervision to prevent potentially serious rebound cardiovascular effects.
Adjustments for age, organ impairment & regimen adherence
Prescribing Beloc (metoprolol) requires special consideration for certain patient groups. For seniors and individuals with kidney issues, treatment typically begins at the lowest dose, usually 25 mg of immediate-release tablets. No renal adjustment proves necessary unless severe chronic kidney disease exists where heightened monitoring becomes essential. Since the liver processes metoprolol, hepatic impairment demands dosing modifications - often halving standard amounts alongside vigilant toxicity checks for symptoms like unusual dizziness or breathing difficulties.
Managing concurrent conditions involves cautious approaches. Diabetics should understand metoprolol might conceal hypoglycaemia indicators such as rapid heartbeat. For asthma sufferers, even Beloc's selective nature doesn't eliminate bronchospasm risks, necessitating slow dosage escalation. Practical adherence strategies include associating doses with daily rituals like morning meals. Pill organisers help track intake, while routine timings minimise skipped doses. Reminder apps provide additional support for those managing complex medication schedules.
Absolute contraindications and warnings
Beloc remains strictly prohibited in specific scenarios due to serious safety concerns. Absolute contraindications include severe bradycardia with heart rates below 50 bpm, significant heart block without pacemaker support, life-threatening decompensated heart failure episodes, and uncontrolled asthmatic conditions. Immediate hypersensitivity reactions to metoprolol formulations also preclude use. Insufficient blood pressure control leading to profound hypotension represents another vital restriction.
Caution applies to relative contraindications where careful monitoring permits use. Controlled diabetic patients require blood glucose vigilance despite optimal management. Those with mild peripheral arterial disease need circulatory assessments, while stable COPD sufferers necessitate regular respiratory checks. Abrupt withdrawal is particularly risky: sudden Beloc discontinuation may provoke rebound angina, dangerous ventricular tachycardia, or unexpected hypertension spikes. Gradual tapering over 1-2 weeks under medical guidance prevents these hazardous events.
Adverse effects & patient management
Beloc sometimes initiates bothersome reactions despite therapeutic benefits. Frequently encountered issues involve fatigue, momentary dizziness, persistently cold hands or feet particularly in colder climates, and mild stomach discomfort. While these often diminish during continued treatment, proper management strategies alleviate discomfort. Alleviate fatigue through morning dosing schedules. Slow positional changes minimise lightheadedness, while layered clothing combats temperature sensitivity.
Though uncommon, severe adverse events require immediate attention. Indicators like fainting episodes, new depressive symptoms, breathing difficulties signalling bronchospasm, or heart rates dropping below 55 bpm warrant urgent medical consultation. Persistent erectile dysfunction issues might necessitate transitions to alternatives like nebivolol. Medical teams should assess sustained low heart rates for potential dose reductions. Incorporating regular pulse measurements into self-monitoring routines helps people stay proactive about cardiovascular responses to Beloc therapy.
Guidelines for proper use
Correct Beloc administration minimises risks while maximising therapeutic benefits:
Timing & administration
- Take with food to reduce gastrointestinal irritation
- Prioritise consistent morning dosing with breakfast for modified-release tablets
Critical safety practices
- Regular blood pressure monitoring - monthly checks during dose adjustment
- Never crush extended-release tablets - alters absorption kinetics
- Avoid abrupt discontinuation - taper over 1-2 weeks minimum
- Storage conditions: Below 25°C in original packaging
Most initial side effects (dizziness, fatigue) resolve within 4 weeks. Contact your GP if persistent symptoms interfere with daily activities.
